[Message Prev][Message Next][Thread Prev][Thread Next]

*To*: email @ redacted*Subject*: [IP] Novolog and Humalog*From*: email @ redacted*Date*: Sat, 9 Mar 2002 16:37:33 EST*Reply-To*: email @ redacted

Do you really want to know? The data in the figure two curve of the Lilly Humalog sheet can be converted to an equation that produces that curve when graphed. With that equation the data can be calculated for any time or time increments. A table of such values at 3 minute intervals was generated. Then, because the Animus delivers a dollop each 3 minutes and because the response to each such is simply additive to whatever is in the blood already, many columns of repeated numbers were placed in the spread sheet. Each column was time offset from the one to its left by 3 minutes. That gave a table of what each time displaced dollop was doing. The leftmost column of the spread sheet page with that stuff on it is the simple sum of what is in that row, row by row. That is, the net insulin is the sum of the individual mini doses each playing through at 3 minute separations. That is how it was done and that is what you will see in the spread sheet. However, you do not have an Animus and I need to know how the Minimed puts in the basal. How much and how often? That and the drop test will allow me to generate a similar but customized basal transient curve for you. The drop test first derivative (the slope) produces the counterpart to fig two. From there the steps are similar but differ in the magnitudes and probably the time steps because of minimed vs animus basal delivery timing. Your friend is overlooking the fact that the diffusion data is implicit in the Humalog data sheet curve. That is a real response in typical of a group of people. Add to that the knowledge that double the dose produces double the result when insulin is injected (that is, the response to dose is linear) and the application of linear superposition takes care of the calculation of how mini doses staged 3 minutes apart combine. Is it good to three decimal places? No. Does it need to be? No. We are only attempting to relate the basal responses to the basal rate time block that is responsible and for that super precision is not needed. As the basal response is monitored, that same dose dynamic gives at least a notion of what insulin intensity that was passed during the transient accounted for the momentarily flat baseline. That facilitates the estimate of what the next attempt at basal rate should be as one works through the proportional scaling. There is no fundamental dependence on highly precise numbers in the above basal rate adjustment process so the fact that some reasonable simplifying assumptions about the mechanism of combination of mini doses was made should not bother anyone. Regarding potency, the assumption is that the fig 2 novolog curve and the fig 2 humalog curve are taken under similar conditions of injection site. They are the average responses of a group of people so individual variation is accounted for. The respective AUC of the two gives the single bolus potency comparison. When we did that with R and H I calculated .9075 and we later measured .91. I have not done that calculation for Novolog vs H because I do not see us using both. I did do it for the basal transient curves (which relate through a different ratio than a single bolus ratio) because I suspected you would attempt to do a pump switch to Novolog and I wanted to forestall a hypo created in ignorance of the ---------------------------------------------------------- for HELP or to subscribe/unsubscribe, contact: HELP@insulin-pumpers.org send a DONATION http://www.Insulin-Pumpers.org/donate.shtml

- Prev by Message:
**Re: [IP] Re: Profile of Samantha <email @ redacted>** - Next by Message:
**Re: [IP] Michael's warranty info** - Prev by thread:
**Re: [IP] Re: Profile of Samantha <email @ redacted>** - Next by thread:
**[IP] Re: Novolog and Humalog/P.S.** - Index(es):